[Could delayed action flanreotide be used as substitute for octreotide in the treatment of dumping syndrome?].
Bouché
O
O
Salmon-Ettersperger
L
L
Frémond
L
L
Thiéfin
G
G
Zeitoun
P
P
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004377:Dumping Syndrome / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D005765:Gastrointestinal Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide
Le lanréotide à libération prolongée peut-il se substituer à l'octréotide dans le traitement du dumping syndrome?